VRPX

Virpax Pharmaceuticals, Inc. Common Stock

VRPX

Market cap $832K

Overview Fund Activity

Delisted

VRPX was delisted on the 3rd of April, 2025.

Back to rankings

About: Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Employees: 2

Healthcare Drug Manufacturers - General

Financial journalist opinion

Virpax Pharmaceuticals Announces Reverse Stock Split

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-25 reverse stock split (“reverse split”) of its common stock, par value $0.0001 per share (“Common Stock”), that will become effective at 12:01 a.m. Eastern Time on.

Virpax Pharmaceuticals Announces Reverse Stock Split

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

BERWYN, Penn.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced positive results from a beagle dog dose range finding (“DRF”) study. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediat.

Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324). The Company will look t.

Virpax Looking to Use MET to Develop Intranasal COVID Vaccine

Virpax's NES100 to be Presented at The Society of Toxicology by NCATS

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its NES100 dose range finding toxicity study will be presented at The Society of Toxicology (SOT) 64th annual meeting and Tox Expo taking place March 16-20th in Orlando, FL. This is a p.

Virpax's NES100 to be Presented at The Society of Toxicology by NCATS

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, would like to congratulate Nanomerics on completing a human study using the Molecular Envelope Technology (MET) and showing no moderate to severe adverse events. Virpax uses MET in its Envelta (NES100) and No.

Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate

On Friday, Virpax Pharmaceuticals, Inc. VRPX completed the full study following the initial Probudur pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and Development Agreement (CRADA).

Penny Stock Virpax Pharmaceuticals Surges On US Army-Performed Preclinical Study For Pain Candidate

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced the completion of the full study that followed the initial Probudur™ pilot study performed by the U.S. Army Institute of Surgical Research (USAISR) under an existing Cooperative Research and D.

Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is pleased to announce its senior director of portfolio management, Matthew Barnes, will be presenting at Outsourcing in Clinical Trial Conference. The Outsourcing in Clinical Trials (OCT) is a leading confer.

Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference

Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering

NEW YORK, NY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading full-service investment banking and financial advisory firm, is proud to announce its role as sole placement agent for Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) in the successful close of its $6 million follow-on offering.

Spartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On Offering

Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

BERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $6.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.20 per share (minus $0.00001 per pr.

Virpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded Warrants

See News Rankings

Charts implemented using Lightweight Charts™